On Tuesday, September 29, AngioDynamics ANGO will release its latest earnings report. Decipher the announcement with Benzinga's help.
Earnings and Revenue
Based on management's projections, AngioDynamics analysts modeled for a loss of $0.07 per share on sales of $65.10 million. AngioDynamics EPS in the same period a year ago totaled $0.08. Revenue was $66.04 million. The Wall Street estimate would represent a 187.5% decline in the company's earnings per share. AngioDynamics's reported EPS has stacked up against analyst estimates in the past like this:
| Quarter | Q4 2020 | Q3 2020 | Q2 2020 | Q1 2019 |
|---|---|---|---|---|
| EPS Estimate | -0.06 | -0.03 | 0.02 | 0.04 |
| EPS Actual | -0.06 | 0.01 | 0.06 | 0.08 |
| Revenue Estimate | 64.30 M | 68.55 M | 71.28 M | 67.52 M |
| Revenue Actual | 58.33 M | 69.78 M | 70.00 M | 66.04 M |
Stock Performance
Over the past 52-week period, shares of AngioDynamics have declined 43.45%.
Considering these returns, long-term shareholders will likely be feeling neutral going into this earnings release.
Don't be surprised to see the stock move on comments made during its conference call. AngioDynamics is scheduled to hold the call at 08:00:00 ET and can be accessed here: https://edge.media-server.com/mmc/p/i2jd82xi
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
